Editorial: TNFRSF agonists: mode of action and therapeutic opportunities
Nataša Obermajer1, Adam Zwolak2, Harald Wajant3
1Oncology R&D, Johnson and Johnson Innovative Medicine, Beerse, Belgium.
Frontiers in Immunology
|November 29, 2023
Abstract
No abstract available in PubMed .


